ArticleMicrobiology spectrum2024
First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.
Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- resaCPE: a rapid, low-cost colorimetric assay for the detection of carbapenemase-producing Enterobacterales.Journal of clinical microbiology · 2026Article
- Within-host co-evolution of KPC variants: plasmid-mediated dissemination ofMicrobiology spectrum · 2026Article
- Profile of Priority Antimicrobial-Resistant Pathogens and the Behavior of Multidrug-Resistant Tuberculosis in the Santiago de Cali District, Colombia.Pathogens (Basel, Switzerland) · 2026Article
- Emergence and dissemination ofMicrobiology spectrum · 2025Article
- Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants.Journal of global antimicrobial resistance · 2025Article
- Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptibleMicrobiology spectrum · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to ceftazidime-avibactam (CZA) due to IMPORTANCE: Latin America and the Caribbean is an endemic region for carbapenemases. Increasingly high rates of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.